• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » The CenterWatch Monthly, June 2016

The CenterWatch Monthly, June 2016

June 1, 2016
CenterWatch Staff

Engaging healthcare providers as research facilitators

Contrary to popular belief, the main reasons physicians are reluctant to re­fer patients to clinical trials have noth­ing to do with fear of losing them to other providers or a lack of knowledge about in­dustry-sponsored clinical research. A new Tufts Center for the Study of Drug Development (CSDD) study found that healthcare providers (HCPs) have a higher-than-expected level of familiarity with clinical research and willingness to refer patients into trials. A significant ma­jority of physicians also reported they are often the primary source of information about clinical trials for their patients and that they actively support their patients’ participation in research.

Capture

Acknowledging the dual enrollment challenge

When a sponsor or CRO is forced to throw out data or write off an en­tire study, millions of dollars are at stake. These are the high stakes that char­acterize the dual enrollment challenge. Enrolling just one ineligible subject al­ready in a simultaneous study could cost a sponsor tens of thousands of dollars or more. When dual enrollment goes un­detected and the entire study must be re­peated, millions of dollars, and more im­portantly time, is wasted. Dual enrollment is often unmeasured and considered by many to be much less common than it once was. However, current data reveal it to be a very real risk that is still widespread.

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Upcoming Events

  • 12Apr

    The Patient Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing